Potential Roles of Cellular Senescence and Inflammaging in Prostate Cancer: Aging Microenvironment, Immune Remodeling, and Therapeutic Implications
Open Access
Abstract
Prostate cancer is common in older men, yet mechanisms linking aging to tumor progression remain incompletely defined. Beyond genetic alterations, aging reshapes the prostate microenvironment through cellular senescence, chronic low-grade inflammation, immune dysfunction, stromal remodeling, metabolic stress, and impaired tissue repair, collectively promoting inflammaging. This persistent inflammatory state may create a permissive niche for tumor initiation, progression, immune evasion, and treatment resistance. Senescent epithelial and stromal cells release cytokines, chemokines, growth factors, matrix-remodeling enzymes, and extracellular vesicles through the senescence-associated secretory phenotype (SASP). In parallel, immune aging alters T-cell subsets, myeloid cells, macrophages, and anti-tumor surveillance. This review summarizes how SASP programs, Th17/Treg imbalance, IL-17/IL-23 signaling, myeloid remodeling, stromal aging, metabolic stress, and immune–stromal–epithelial crosstalk shape prostate cancer biology. We further discuss therapeutic implications, including cytokine modulation, senescence-directed therapy, metabolic intervention, and biomarker-guided strategies. This review highlights key knowledge gaps and proposes a framework for age-aware prostate cancer research, biomarker development, and therapeutic strategies.Keywords
All Related Versions
Funding Information
- National Institutes of Health (1R01CA255802-05)
- National Institute of General Medical Sciences (P20GM103629)
This publication has 150 references indexed in Scilit:
- A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancerInvestigational New Drugs, 2026
- Tumor microenvironment-mediated immune evasion and resistance in prostate cancer: mechanisms, cross-talk, and therapeutic opportunitiesClinical and Experimental Medicine, 2025
- Oxidative stress as a catalyst in prostate cancer progression: unraveling molecular mechanisms and exploring therapeutic interventionsDiscover Oncology, 2025
- Targeting obesity, metabolic syndrome, and prostate cancer: GLP-1 agonists as emerging therapeutic agentsDiscover Oncology, 2025
- Radiotherapy and inflammaging: the influence of prostate cancer radiotherapy on systemic inflammationWorld Journal of Urology, 2024
- CD4+ T helper 17 cell response of aged mice promotes prostate cancer cell migration and invasionThe Prostate, 2020
- Targeting Th17‐IL‐17 Pathway in Prevention of Micro‐Invasive Prostate Cancer in a Mouse ModelThe Prostate, 2017
- Interleukin‐17 promotes development of castration‐resistant prostate cancer potentially through creating an immunotolerant and pro‐angiogenic tumor microenvironmentThe Prostate, 2014
- Role of the stromal microenvironment in carcinogenesis of the prostateInternational Journal of Cancer, 2003
- The serial cultivation of human diploid cell strainsExperimental Cell Research, 1961